Saturday 4th of February marks World Cancer Day 2012
Did you know that cancer was accountable for approximately 7.6 million deaths in 2008 and is the second most common cause of death globally ? Did you also know that many of these deaths were avoidable? With greater prevention, earlier detection and improved access to innovative treatments the numbers of people suffering from cancer can be greatly reduced.
Healthcare Biotechnology is leading the way in tackling the disease. In particular the rise of monoclonal antibodies is profoundly changing the landscape of cancer treatment for the better. Currently, long-established and new cancer monoclonal antibodies as well as emerging applications such as cancer vaccine provides valued treatments – and sometimes cure – for cancer patients.
In North America and the EU, approximately 70% of anti-cancer treatments are driven largely by innovations derived from biotechnology. These innovations have improved quality of life, delayed disease progression, and helped prolong survival for patients battling different types of cancer—including breast, colon, lymphoma, leukemia, and kidney .
With one in three people being diagnosed with cancer at some point in their life, access to better treatment and earlier detection is vital. Modern healthcare biotechnology has the potential to meet these demands by providing personalised, innovative, safe and effective healthcare products for patients.